Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer.

Erica Stringer-Reasor,Barbara O’Brien,Ariel Topletz-Erickson,Jason B White,Mina Lobbous,Kristen O. Riley,Jennifer L. Childress,Kim LaMaster,Michelle E. Melisko,Aki Morikawa,John de Groot,Ian E. Krop,Vicente Valero,Mothaffar F. Rimawi,Antonio C. Wolff,Debu Tripathy,Nancy U. Lin,Rashmi K. Murthy

Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer.

2021

Erica Stringer-Reasor
Barbara O’Brien
Ariel Topletz-Erickson
Jason B White
Mina Lobbous
Kristen O. Riley
Jennifer L. Childress
Kim LaMaster
Michelle E. Melisko
Aki Morikawa
John de Groot
Ian E. Krop
Vicente Valero
Mothaffar F. Rimawi
Antonio C. Wolff
Debu Tripathy
Nancy U. Lin
Rashmi K. Murthy

1044Background: Tucatinib is a potent and highly selective HER2-targeted tyrosine kinase inhibitor approved for use in combination with trastuzumab and capecitabine for patients with metastatic HER...

Keywords:

Internal medicine
Oncology
Medicine
highly selective
Pharmacokinetics
Leptomeningeal metastasis
Tyrosine-kinase inhibitor
Capecitabine
Trastuzumab
HER2 Positive Breast Cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations